The v-myb oncogene is a potent inducer of acute myeloblastosis in chickens. V-myb is a truncated version of the c-myb proto-oncogene, an important regulator of hematopoiesis required for the correct development of most blood cell lineages in vertebrates (reviewed in Weston, 1998) . Despite its close links with retrovirally-induced leukemias in chickens, deregulated c-myb is not a mainstream mammalian oncogene. In adult mice, truncation of c-myb by retrovirallymediated insertional mutagenesis results in the induction of promonocytic leukemias with a latency of about 100 days, but only if the mice are primed with the tumor promoter pristane (Mushinski et al., 1983) . Infection of mouse bone marrow with viruses expressing truncated c-myb leads to the generation of CSF-dependent myeloid cell lines, but the cells are not tumorigenic in vivo (Gonda et al., 1989) . In the mouse at least, mutation, generally by truncation, is required for c-myb to be deregulated; simple overexpression does not result in the formation of tumors (Furuta et al., 1993) .
In human tumors, very few chromosomal abnormalities resulting in the ampli®cation or mutation of cmyb have been described (Alitalo et al., 1984; Jacobs et al., 1994; Pelicci et al., 1984) , and the c-myb locus does not feature in any of the chromosomal translocations occurring in human hematopoietic neoplasms (reviewed in Sanchez-Garcia, 1997). However, c-myb is frequently over-expressed in human myeloid and lymphoid leukemias. Experiments from the chicken and mouse systems suggest that v-myb can act to induce tumors in both these lineages Wol, 1996) , and so it is possible that deregulation of c-myb might be relevant to the development of human myeloid and lymphoid leukemias. Certainly, sustained expression of c-myb appears to be important for the continued proliferation of leukemic cells; antisense experiments argue that removing c-myb mRNA results in their death (Calabretta et al., 1991) .
In order to explore the tumorigenic potential of vmyb in the lymphoid lineage, we previously generated lines of transgenic mice which express the v-Myb protein in a T-cell-speci®c fashion throughout T cell development. The mice had increased numbers of thymocytes and mature T cells, and the ratio of helper CD4 + CD8
7 to cytotoxic CD4 7 CD8 + cells had changed, as there were abnormally high numbers of helper cells. 70% of animals developed high grade T cell lymphomas, but with prolonged latency; the average age of onset was 60 weeks . Intriguingly, the long period of latency, followed by the development of acute lymphoma, is very reminiscent of lymphomas induced by dysregulation of the bcl-2 oncogene (Linette et al., 1995) . Loss of Myb activity in T cells has been shown to lead to an increased susceptibility to apoptosis (Taylor et al., 1996) , and so it is possible that v-Myb and bcl-2 both cause lymphomas by prolonging the lifetime of a pool of cells, and thereby increasing the chance of further somatic mutations leading to tumor formation.
To examine what the cellular mutations leading to neoplasia in the v-Myb transgenics might be, we have searched for oncogenes capable of cooperating with vMyb by infecting neonatal mice from the transgenic line vMyb4 with Moloney murine leukemia virus (MMuLV). This technique, pioneered by the laboratories of Berns and Adams (reviewed in Jonkers and Berns, 1996) , exploits the fact that slow-transforming retroviruses such as M-MuLV cause tumors by inserting near to cellular oncogenes, and aberrantly activating them. The deregulated endogenous gene can cooperate with an exogenously expressed oncogene to accelerate tumor formation, and the proviral M-MuLV sequences can then be used as a marker to identify the deregulated genomic locus. When we infected vMyb4 transgenics with M-MuLV, T cell lymphomas developed with a latency of 13 weeks, as opposed to 60 weeks in uninfected vMyb4 animals. Analysis of DNA recovered from the transgenic tumors showed that in 73% of cases, the M-MuLV provirus had integrated into either the c-myc or the N-myc loci, demonstrating that v-myb and c-myc can cooperate in the genesis of T cell lymphomas.
Acceleration of tumorigenesis by MuLV injection
In our original experiments on the eects of overexpressing v-Myb in T cells, we analysed two lines of mice, vMyb1 and vMyb4, in which the avian myelobastosis virus (AMV) v-myb gene was expressed from a CD2 LCR b-globin promoter cassette on an inbred CBA/Ca background. vMyb4 animals had slightly higher levels of expression of the transgene, and developed lymphomas on average 2 months earlier than their vMyb1 counterparts, at around 60 weeks of age . To test for acceleration of tumor formation, we injected 33 vMyb4 heterozygotes and 34 non-transgenic littermates neonatally with high-titer supernatant from the MMuLV expressing cell line clone 1A (Jaenisch et al., 1975) . Figure 1a shows that by 21 weeks of age, all the vMyb4 mice had succumbed to tumors, whereas only one of their nontransgenic siblings had died. The mean age of onset for the accelerated vMyb4 tumors was 12.7 weeks (89 days), representing a substantial decrease from the original latency of vMyb4 tumors. Moribund animals typically had gross splenomegaly, some thymic enlargement, and large tumors in their mesenteric lymph nodes. In®ltration of the kidneys and liver ( Figure 1b , right panel) were frequently seen, and abnormal blasts were present in the blood ( Figure 1b , left panel).
The phenotype of vMyb4 accelerated tumors was dierent from that of M-MuLV-induced tumors in nontransgenic controls. Seven of 34 nontransgenics (21%) developed thymomas which dominated their chest cavities, and had slightly enlarged spleens and tumors of the mesenteric lymph nodes. The average age of onset for these tumors was 22.5 weeks (158 days).
At 24 weeks of age, when all the remaining nontransgenic controls were sacri®ced, a further three mice had enlarged thymuses but were otherwise normal, and eight more had normal-sized thymuses, but with an abnormal thymocyte pro®le, comprising mainly CD4 + CD8
7 cells. The remaining 16 animals were normal. This slow development of tumors can be attributed to the inbred CBA/Ca background of the experimental animals; mice of this strain are known to be resistant to M-MuLV tumor induction (Gisselbrecht et al., 1978; Hartley et al., 1983) .
Immunophenotyping of the vMyb4 tumors characterized them as of T cell origin. A typical staining pro®le for thymus, spleen and tumor is shown in Figure 2a . Table 1 + cells were lost upon passage in nu/nu mice. There was also some partial loss of the CD4 + marker upon passage, reminiscent of the situation in the original vMyb4 delayed onset lymphomas . Where examined, the nontransgenic tumors looked very Table 1 ), or an Empim-1 (not transgenic for vMyb) mouse, both injected neonatally with M-MuLV. Tissue preparation and blotting, using an antibody (2.74) directed against AMV v-Myb, were as previously described , except that signal was detected with ECL reagents similar to vMyb4 tumors. All tumors assessed were clonal or near-clonal, as judged by rearrangement of the endogenous abTCR (data not shown). Figure 2b shows that the v-myb transgene was still being expressed in a vMyb4 tumor, as contrasted with an M-MuLV tumor induced in a dierent strain of transgenic mice (Empim-1).
Myc loci are frequent integration targets in accelerated vMyb4 tumors
We prepared DNA from the vMyb4 accelerated tumors, and used Southern blotting to determine where the M-MuLV proviruses had integrated. DNA was digested with KpnI, and probed for c-myc and Nmyc integrations, with EcoRI for g®-1 (pal)-1 integrations, and with EcoRV for pim-1 integrations (data not shown). Table 2 summarizes the results of these experiments. 20/33 tumors had integrations in the cmyc locus, two tumors had both N-and c-myc integrations, and two had integrations in the N-myc locus. In nine of these tumors, there were further integrations in the pim-1 and g®-1 loci, and in one tumor, a pim-1 integration was detected in the absence of myc or g®-1 integrations. Therefore, in 73% of tumors, the M-MuLV provirus had inserted into either the c-or N-myc loci.
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exon 1 (Figure 3 ). All but one of the proviruses were oriented away from the myc gene. The mechanism of cmyc activation in these tumors therefore appears to be by enhancer insertion, as has been previously described for murine T cell lymphomas (reviewed in Kung et al., 1991) . A further ®ve tumors had integrations at unidenti®ed loci. To attempt to identify these loci, we performed inverse PCR using M-MuLV-speci®c primers as described in (van Lohuizen et al., 1991) (data not shown). The genomic sequences derived were not present in any databases; we are currently using them as probes to further study the integration events.
Overexpression of c-myc in accelerated vMyb4 tumors
We performed Northern blotting and RNAse protection assays on a selection of tumors either carrying or not carrying an integration in c-myc. Data from an RNAse protection assay are shown schematically in Figure 4 . The c-myc-speci®c signal has been normalized using GAPDH as an internal control. All ®ve tumors carrying a c-myc integration had 2 ± 3-fold increased levels of c-myc mRNA relative to normal thymus. Tumors without a c-myc integration showed variable levels of c-myc transcription; in two samples, P30 and P31, c-myc mRNA was greatly increased, but in the other samples, it remained at normal levels.
v-myb and c-or N-myc are cooperating oncogenes
We show here that v-Myb and Myc are able to cooperate to generate T cell tumors in mice, with a latency of about 13 weeks. Given the fairly rapid onset of the tumors, why is it that the c-myb locus has never been found as an integration target in c-myc transgenic mice infected with M-MuLV? Two integration loci, ahi-1 and mis-2, have been mapped to 35 kb and 160 kb respectively of the 3' end of c-myb (Jiang et al., 1994; Villeneuve et al., 1993) , but mutation at neither appears to cause changes in c-myb expression.
There are many reasons that an oncogene is not necessarily detectable by insertional mutagenesis. The most obvious, that its activation requires more than the simple overexpression and/or truncation method favored by retroviral insertion, clearly does not apply to c-myb, as it can be activated by M-MuLV in promonocytic leukemias (Wol, 1996) . It is possible that the rate-limiting step to tumorigenesis which cmyb deregulation might override is not present in MMuLV infections. In addition to its role as an insertional mutagen, M-MuLV induces a preleukemic expansion of lymphoid and myeloid precursors in spleen and bone marrow, and also mobilizes endogenous recombinant viruses which accelerate leukemogenesis (reviewed in van Lohuizen and Berns, 1990) . These responses are an important component of M-MuLVmediated tumor formation. If v-Myb is involved in the same aspects of maintenance or production of preleukemic target cells, it may be super¯uous as a later integration event in an M-MuLV infection. However, when v-Myb is present as the ®rst activating event, acceleration of lymphomagenesis would occur upon M-MuLV infection due to proviral activation of other cellular proto-oncogenes. Interestingly, v-Myb transgenic animals resemble the T-cell-targeted Em-bcl-2 transgenics: bcl-2 overexpression causes low penetrance slow onset peripheral T cell lymphomas (Linette et al., 1995; Shinto et al., 1995) ; bcl-2 is never found activated in M-MuLV tumors, but upon infection with Numbers refer to the tumor involved. Points of integration were determined by PCR using two sets of primers. Primer A (GACTCATGTTTCTGGTTGG), in the c-myc promoter was paired with primer C (CCTTGCAAAATGGCGTTAC) in the U3 region of M-MuLV. Primer B (AGATGTTTCCAGGGTGCC), in c-myc exon 1, was paired with primer D (GAGCTGAGT-GAGGCGAGTC) in the U3 region of M-MuLV. 200 ng of genomic DNA was ampli®ed by 30 cycles of denaturation (948C, 1 min), annealing (568C, 2 min), and extension (728C, 2 min), using both primer sets Figure 4 Histogram showing levels of c-myc expression, normalized to a GAPDH internal control, in accelerated vMyb4 tumors. Data were derived by RNAse protection mapping, and are expressed as a fold change relative to normal thymic c-myc mRNA levels. Total RNA was prepared from frozen tissues in a Polytron homogenizer, using RNAzol B (Biogenesis Ltd). RNAse protection using a GAPDH internal control was performed as described (Taylor et al., 1996) . The c-myc probe was derived from pSV2mycS M-MuLV, Em-bcl-2 animals show acceleration of lymphomagenesis and integrations in the c-myc and pim-1 loci (Shinto et al., 1995) . Given that both c-myb and bcl-2 are involved in protecting lymphocytes from apoptosis (Strasser et al., 1991; Taylor et al., 1996; Vaux et al., 1988) , maybe it is this function which is not required in the presence of M-MuLV.
Our results are of interest in the light of a recent report showing that the serine-threonine kinase Pim-1 is able to activate c-Myb protein via an interaction with the transcriptional co-activator p100 (Leverson et al., 1998) . As is well known, Pim-1 and c-Myc are eager collaborators in the induction of lymphomas in mice (van Lohuizen et al., 1989 (van Lohuizen et al., , 1991 . The cooperation we have observed between v-Myb and c-Myc makes it possible that c-Myb lies downstream of Pim-1 on the same pathway to tumorigenesis. It is unlikely that c-Myb is the only relevant downstream target for Pim-1, as one of the accelerated tumors described here contained a pim-1 integration, and we have preliminary evidence that v-Myb and Pim-1 can cooperate to cause lymphomas (K Weston unpubl.). However, it will be of great interest to determine whether c-Myb is required for the oncogenic activity of Pim-1; experiments to test this idea are currently underway.
